Trastuzumab - Mechanism of action and use in clinical practice Journal Article
| Author: | Hudis, C. A. |
| Article Title: | Trastuzumab - Mechanism of action and use in clinical practice |
| Abstract: | OVEREXPRESSION OF HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR type 2 (HER2, also referred to as HER2/neu or ErbB-2), a 185-kD receptor first described more than two decades ago,1 occurs in 20 to 30% of invasive breast carcinomas. In general, patients with breast-cancer cells that overexpress this receptor or that have a high copy number of its gene have decreased overall survival and may have differential responses to a variety of chemotherapeutic and hormonal agents.2-6 Thus, strategies to target HER2 appear to be important in treating breast cancer. One such medication is trastuzumab (Herceptin, Genentech), a humanized monoclonal antibody. Trastuzumab binds to the extracellular juxtamembrane domain of HER2 and inhibits the proliferation and survival of HER2-dependent tumors. It is approved by the Food and Drug Administration (FDA) for patients with invasive breast cancers that overexpress HER2. This review considers trastuzumab's mechanism of action and its clinical value. Copyright © 2007 Massachusetts Medical Society. |
| Keywords: | signal transduction; cancer survival; clinical trial; review; bevacizumab; cisplatin; doxorubicin; monotherapy; nonhuman; side effect; antineoplastic agents; capecitabine; gemcitabine; paclitaxel; adjuvant therapy; chemotherapy, adjuvant; clinical practice; cell proliferation; gene overexpression; carboplatin; breast cancer; bone marrow suppression; heart disease; nausea; vomiting; epidermal growth factor receptor 2; cyclophosphamide; receptor, epidermal growth factor; food and drug administration; breast neoplasms; docetaxel; protein tyrosine kinase inhibitor; loading drug dose; cancer invasion; antibodies, monoclonal; drug mechanism; celecoxib; cardiotoxicity; cancer cell; epirubicin; receptor, erbb-2; taxane derivative; corticosteroid; trastuzumab; navelbine; anthracycline; breast metastasis; heart left ventricle ejection fraction; congestive heart failure; lapatinib; hypersensitivity reaction; antihistaminic agent; pertuzumab; antiinflammatory agent; neu differentiation factor; gamma urogastrone; 17 allylamino 17 demethoxygeldanamycin |
| Journal Title: | New England Journal of Medicine |
| Volume: | 357 |
| Issue: | 1 |
| ISSN: | 0028-4793 |
| Publisher: | Massachusetts Medical Society |
| Date Published: | 2007-07-05 |
| Start Page: | 39 |
| End Page: | 51 |
| Language: | English |
| DOI: | 10.1056/NEJMra043186 |
| PUBMED: | 17611206 |
| PROVIDER: | scopus |
| DOI/URL: | |
| Notes: | --- - "Cited By (since 1996): 399" - "Export Date: 17 November 2011" - "CODEN: NEJMA" - "Source: Scopus" |
